These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 12074691)

  • 1. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
    Danesi R; Fogli S; Gennari A; Conte P; Del Tacca M
    Clin Pharmacokinet; 2002; 41(6):431-44. PubMed ID: 12074691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epirubicin. Clinical pharmacology and dose-effect relationship.
    Robert J
    Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
    Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
    Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthracyclines in the treatment of cancer. An overview.
    Hortobágyi GN
    Drugs; 1997; 54 Suppl 4():1-7. PubMed ID: 9361955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity].
    Vasyuk YA; Shkolnik EL; Nesterov VV; Shkolnik LD; Varlan GV
    Kardiologiia; 2016 Dec; 56(12):72-79. PubMed ID: 28290807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
    Kuffel MJ; Reid JM; Ames MM
    Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose optimization of anthracyclines.
    de Valeriola D
    Anticancer Res; 1994; 14(6A):2307-13. PubMed ID: 7825964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contradistinction between doxorubicin and epirubicin: in-vitro interaction with blood components.
    Ramanathan-Girish S; Boroujerdi M
    J Pharm Pharmacol; 2001 Jun; 53(6):815-21. PubMed ID: 11428657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
    Wadler S; Fuks JZ; Wiernik PH
    J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of low-protein diet on anthracycline pharmacokinetics and cardiotoxicity.
    El-Demerdash E; Ali AA; El-Taher DE; Hamada FM
    J Pharm Pharmacol; 2012 Mar; 64(3):344-52. PubMed ID: 22309266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
    Hurteloup P; Ganzina F
    Drugs Exp Clin Res; 1986; 12(1-3):233-46. PubMed ID: 3525075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.
    Plosker GL; Faulds D
    Drugs; 1993 May; 45(5):788-856. PubMed ID: 7686469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and metabolism of anthracyclines.
    Robert J; Gianni L
    Cancer Surv; 1993; 17():219-52. PubMed ID: 8137342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
    Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer.
    Coukell AJ; Faulds D
    Drugs; 1997 Mar; 53(3):453-82. PubMed ID: 9074845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics of new anthracyclines].
    Robert J
    Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of epirubicin.
    Robert J
    Clin Pharmacokinet; 1994 Jun; 26(6):428-38. PubMed ID: 8070217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.
    Fokkema E; Verweij J; van Oosterom AT; Uges DR; Spinelli R; Valota O; de Vries EG; Groen HJ
    Br J Cancer; 2000 Feb; 82(4):767-71. PubMed ID: 10732743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.
    Hollingshead LM; Faulds D
    Drugs; 1991 Oct; 42(4):690-719. PubMed ID: 1723369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.